These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Subscribe To Our Newsletter & Stay Updated
